Skip to main content
Clinical Trials/NCT03704415
NCT03704415
Completed
Not Applicable

Aggravated Airway Inflammation: Research on Genomics and Optimal Operative Treatment (AirGOs Operative)

Helsinki University Central Hospital3 sites in 2 countries97 target enrollmentOctober 23, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sinusitis, Chronic
Sponsor
Helsinki University Central Hospital
Enrollment
97
Locations
3
Primary Endpoint
Sino-nasal outcome test (SNOT-22)
Status
Completed
Last Updated
last year

Overview

Brief Summary

This randomized study compares operative techniques in chronic rhinosinusitis with polyposis (CRSwNP) surgery. It aims to evaluate outcomes in asthma and CRSwNP, safety and costs. The investigators want to see if patients with certain clinical and/or genetic predispositions will benefit from extended surgery. They also aim to find biomarkers for detection and management models for of severe airway inflammation and to further develop markers for progressive disease forms.

Detailed Description

Please see study protocol

Registry
clinicaltrials.gov
Start Date
October 23, 2018
End Date
October 23, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Paula Virkkula

Chief Physician in Rhinology

Helsinki University Central Hospital

Eligibility Criteria

Inclusion Criteria

  • Patient not responding to conservative treatment of 3 months of nasal steroid drops
  • Nasal polyp score ≥ 4/8
  • SNOT-22 ≥ 30
  • Lund-Mackay CT score ≥ 14
  • One previous endoscopic sinus surgery or at least one peroral corticosteroid course or at least 3 courses of antibiotics within 2 years

Exclusion Criteria

  • Age \<18 years, age \> 65 years
  • Complication of CRS (f.e. mucocele, invasive fungal rhinosinusitis)
  • Other diagnosis than CRSwNP (inverted papilloma, antrochoanal polyp etc.)
  • Previous external sinus surgery or Draf 3 procedure (or indication for external approaches or Draf 3
  • Bleeding diathesis
  • Pregnancy/ breastfeeding
  • Cystic fibrosis
  • Primary ciliary dyskinesia (PCD)
  • Sarcoidosis
  • Granulomatosis with polyangitis (GPA)

Outcomes

Primary Outcomes

Sino-nasal outcome test (SNOT-22)

Time Frame: Baseline, Post-intervention every 3 months during 2 years

Change from baseline in patient symptoms as measured by the Sino-Nasal Outcomes Test (SNOT-22) survey. Scores are measured from 0-5 in a 22 item validated survey. Total scores range from 0-110 with higher scores indicating greater burden of sinonasal symptoms.

Study Sites (3)

Loading locations...

Similar Trials